A few days ago I published my portfolio with average entries:
SpaceX (SPCX), $123 - up 20%
Oscar Health (OSCR), $13.19 - up 150%
Amazon (AMZN), $247.55 - flat
Eli Lilly (LLY), $1,186 - up 5%
Natera (NTRA), $210 - up 90%
Palantir (PLTR), $133 - up 43% (sold)
Recursion (RXRX), $3 - up 50% (sold)
These are the results of the way I actually invest: identify category-defining companies, size them properly, and stay with the winners while the thesis is intact. The returns speak for themselves when you stack them against almost any other research product on Substack or elsewhere.
I am not a 20 stock guy & you already know that. That is likely why most of you are here. I make large, high-conviction bets on businesses that can absorb significant capital and still compound meaningfully. The goal is to increase net worth as efficiently as possible. When a name has delivered what I underwrote, and a clearer opportunity is visible, I move.
That is exactly what is happening now.
I am exiting…